Johnson & Johnson announced it will discontinue sales of its LINX Reflux Management System in certain international markets, citing commercial considerations rather than safety concerns.
The medical device, designed for patients with chronic gastroesophageal reflux disease (GERD), uses a flexible ring of magnetic beads implanted around the lower esophageal sphincter to prevent stomach acid from flowing back into the food pipe.
A company spokesperson confirmed the decision followed “a thorough evaluation of market conditions and the ability to effectively serve each market.” The spokesperson emphasized that the move does not reflect any change in the product’s safety or effectiveness.
While J&J has not disclosed the specific countries it will exit, Bloomberg News reported earlier that the withdrawal from markets outside the U.S. could take effect by the end of March, according to a letter the company sent to physicians.
The LINX device will continue to remain available in the United States.
